What will Brexit mean for pharma companies on both sides of the Atlantic? Given the ‘special relationship’ between the US and UK – and the particular track record of collaboration in the pharma industry – many people within and beyond the industry are trying to assess what the future will now hold.
In order to try to determine this, life sciences expert Alacrita conducted a survey to gauge the views of C-suite biotech executives in the US.
The results, outlined in the infographic below, show what these influential figures think about the European market now – and what they think might change when it comes to clinical trials and establishing an HQ five to ten years after Brexit…
Provided by Alacrita
